Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(29%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
3
43%
Ph phase_3
1
14%
Ph phase_4
3
43%

Phase Distribution

0

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting2
Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (42.9%)
Phase 31 (14.3%)
Phase 43 (42.9%)

Trials by Status

completed229%
recruiting229%
not_yet_recruiting229%
unknown114%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_2

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964
recruitingphase_3

A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

NCT06589765
completedphase_4

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

NCT05704088
not_yet_recruitingphase_4

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

NCT06442280
not_yet_recruitingphase_2

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

NCT06012266
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06762964Phase 2

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Recruiting
NCT06589765Phase 3

A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

Recruiting
NCT05704088Phase 4

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

Completed
NCT06442280Phase 4

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Not Yet Recruiting
NCT06012266Phase 2

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Not Yet Recruiting
NCT04287387Phase 4

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Unknown
NCT03180489Phase 2

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7